Temat: "Pharmacogenomic Variants" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Presence of the aldehyde dehydrogenase 2 variant ALDH2*2 considerably increases EC 50 of nitroglycerin.
Autorzy :: Ushijima K; Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, 329-0498, Japan. .; Division of Pharmaceutics, Faculty of Pharmaceutical Sciences, Sanyo-Onoda City University, Yamaguchi, Japan. .
Ogami C; Department of Medical Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Tsuji Y; School of Pharmacy, Nihon University, Chiba, Japan.
Nagano T; Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, 329-0498, Japan.; Department of Anesthesiology and Critical Care Medicine, Jichi Medical University, Tochigi, Japan.
Fujimura A; Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, 329-0498, Japan.; Pokaż więcej
Źródło :: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2021 Mar; Vol. 77 (3), pp. 431-433. Date of Electronic Publication: 2020 Oct 10.
Typ publikacji :: Letter
MeSH Terms :: Pharmacogenomic Variants*
Polymorphism, Genetic*
Aldehyde Dehydrogenase, Mitochondrial/*genetics
Nitroglycerin/*pharmacokinetics
Vasodilation/*drug effects
Vasodilator Agents/*pharmacokinetics
Aldehyde Dehydrogenase, Mitochondrial/metabolism ; Biological Variation, Population ; Dose-Response Relationship, Drug ; Humans ; Nitroglycerin/administration & dosage ; Pharmacogenetics ; Vasodilator Agents/administration & dosage
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: For better drugs, diversify clinical trials.
Autorzy :: Bumpus NN; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. .; Pokaż więcej
Źródło :: Science (New York, N.Y.) [Science] 2021 Feb 05; Vol. 371 (6529), pp. 570-571.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Genome, Human*
Pharmacogenomic Variants*
Pharmaceutical Preparations/*metabolism
Cytochrome P-450 Enzyme System/genetics ; Humans ; Pharmacogenetics
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 3 3.

Tytuł :: CYP2C19 Loss-of-Function is Associated with Increased Risk of Ischemic Stroke after Transient Ischemic Attack in Intracranial Atherosclerotic Disease.
Autorzy :: Patel PD; Vanderbilt University School of Medicine, 1161 21st Ave S # D3300, Nashville, TN 37232, United States; Surgical Outcomes Center for Kids, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, United States. Electronic address: .
Vimalathas P; Vanderbilt University School of Medicine, 1161 21st Ave S # D3300, Nashville, TN 37232, United States.
Niu X; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States.
Shannon CN; Surgical Outcomes Center for Kids, Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, United States; Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, United States.
Denny JC; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States.
Peterson JF; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States.
Chitale RV; Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, United States.
Fusco MR; Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, United States.; Pokaż więcej
Źródło :: Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association [J Stroke Cerebrovasc Dis] 2021 Feb; Vol. 30 (2), pp. 105464. Date of Electronic Publication: 2020 Nov 24.
Typ publikacji :: Journal Article
MeSH Terms :: Pharmacogenomic Variants*
Clopidogrel/*adverse effects
Cytochrome P-450 CYP2C19/*genetics
Drug Resistance/*genetics
Intracranial Arteriosclerosis/*drug therapy
Ischemic Attack, Transient/*prevention & control
Ischemic Stroke/*prevention & control
Platelet Aggregation Inhibitors/*adverse effects
Aged ; Clopidogrel/administration & dosage ; Databases, Factual ; Female ; Humans ; Intracranial Arteriosclerosis/complications ; Intracranial Arteriosclerosis/diagnostic imaging ; Ischemic Attack, Transient/diagnostic imaging ; Ischemic Attack, Transient/etiology ; Ischemic Stroke/diagnostic imaging ; Ischemic Stroke/etiology ; Male ; Middle Aged ; Platelet Aggregation Inhibitors/administration & dosage ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Incorporating SULF1 polymorphisms in a pretreatment CT-based radiomic model for predicting platinum resistance in ovarian cancer treatment.
Autorzy :: Yi X; Department of Radiology, Xiangya Hospital, Central South University, Changsha 410008, PR China; National Clinical Research Center for Geriatric Disorders (Xiangya Hospital), Central South University, Changsha 410008, PR China.
Liu Y; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, PR China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410008, PR China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha 410008, PR China; National Clinical Research Center for Geriatric Disorders, Changsha 410008, PR China.
Zhou B; Xiangya School of Medicine, Central South University, Changsha 410013, PR China.
Xiang W; Department of Radiology, Hunan Provincial Tumor Hospital, The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha 410008, PR China.
Deng A; Department of Radiology, Hunan Provincial Tumor Hospital, The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha 410008, PR China.
Fu Y; Department of Radiology, Hunan Provincial Tumor Hospital, The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha 410008, PR China.
Zhao Y; Department of Radiology, Hunan Provincial Tumor Hospital, The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha 410008, PR China.
Ouyang Q; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, PR China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410008, PR China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha 410008, PR China; National Clinical Research Center for Geriatric Disorders, Changsha 410008, PR China.
Liu Y; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, PR China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410008, PR China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha 410008, PR China; National Clinical Research Center for Geriatric Disorders, Changsha 410008, PR China.
Sun Z; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, PR China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410008, PR China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha 410008, PR China; National Clinical Research Center for Geriatric Disorders, Changsha 410008, PR China.
Zhang K; Hunan Provincial Tumor Hospital, The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha 410008, PR China.
Li X; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, PR China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410008, PR China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha 410008, PR China; National Clinical Research Center for Geriatric Disorders, Changsha 410008, PR China.
Zeng F; Department of Radiology, Xiangya Hospital, Central South University, Changsha 410008, PR China; National Clinical Research Center for Geriatric Disorders (Xiangya Hospital), Central South University, Changsha 410008, PR China. Electronic address: .
Zhou H; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, PR China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410008, PR China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha 410008, PR China; National Clinical Research Center for Geriatric Disorders, Changsha 410008, PR China.
Chen BT; Department of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA, United States.; Pokaż więcej
Źródło :: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2021 Jan; Vol. 133, pp. 111013. Date of Electronic Publication: 2020 Nov 20.
Typ publikacji :: Journal Article; Validation Study
MeSH Terms :: Multidetector Computed Tomography*
Pharmacogenomic Testing*
Pharmacogenomic Variants*
Polymorphism, Single Nucleotide*
Radiation Genomics*
Antineoplastic Agents/*therapeutic use
Drug Resistance, Neoplasm/*genetics
Ovarian Neoplasms/*drug therapy
Platinum Compounds/*therapeutic use
Sulfotransferases/*genetics
Chemotherapy, Adjuvant ; Cytoreduction Surgical Procedures ; Female ; Humans ; Machine Learning ; Middle Aged ; Observer Variation ; Ovarian Neoplasms/diagnostic imaging ; Ovarian Neoplasms/genetics ; Predictive Value of Tests ; Reproducibility of Results ; Retrospective Studies
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers.
Autorzy :: Zubiaur P; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain; Unidad de Investigación Clínica y Ensayos Clínicos (UICEC), Hospital Universitario de La Princesa, Plataforma SCReN (Spanish Clinical Research Network), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
Soria-Chacartegui P; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
Koller D; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
Navares-Gómez M; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
Ochoa D; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain; Unidad de Investigación Clínica y Ensayos Clínicos (UICEC), Hospital Universitario de La Princesa, Plataforma SCReN (Spanish Clinical Research Network), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
Almenara S; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
Saiz-Rodríguez M; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain; Research Unit of Hospital Universitario de Burgos (HUBU), Castilla y León, Spain.
Mejía-Abril G; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain; Unidad de Investigación Clínica y Ensayos Clínicos (UICEC), Hospital Universitario de La Princesa, Plataforma SCReN (Spanish Clinical Research Network), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
Villapalos-García G; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
Román M; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain; Unidad de Investigación Clínica y Ensayos Clínicos (UICEC), Hospital Universitario de La Princesa, Plataforma SCReN (Spanish Clinical Research Network), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
Martín-Vílchez S; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain; Unidad de Investigación Clínica y Ensayos Clínicos (UICEC), Hospital Universitario de La Princesa, Plataforma SCReN (Spanish Clinical Research Network), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain.
Abad-Santos F; Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain; Unidad de Investigación Clínica y Ensayos Clínicos (UICEC), Hospital Universitario de La Princesa, Plataforma SCReN (Spanish Clinical Research Network), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Electronic address: .; Pokaż więcej
Źródło :: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2021 Jan; Vol. 133, pp. 111087. Date of Electronic Publication: 2020 Dec 08.
Typ publikacji :: Journal Article; Observational Study
MeSH Terms :: Pharmacogenomic Variants*
Polymorphism, Genetic*
Antipsychotic Agents/*pharmacokinetics
Enzymes/*genetics
Membrane Transport Proteins/*genetics
Olanzapine/*pharmacokinetics
Adult ; Antipsychotic Agents/administration & dosage ; Antipsychotic Agents/adverse effects ; Biotransformation ; Clinical Trials as Topic ; Female ; Genetic Association Studies ; Genotype ; Healthy Volunteers ; Humans ; Male ; Olanzapine/administration & dosage ; Olanzapine/adverse effects ; Phenotype ; Risk Factors ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Autorzy :: Langer T; Department of Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, Germany.
Clemens E; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, the Netherlands.
Broer L; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.
Maier L; Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University Medical Center, Ulm, Germany.
Uitterlinden AG; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.
de Vries ACH; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, the Netherlands.
van Grotel M; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Pluijm SFM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Binder H; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany; Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
Mayer B; Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany.
von dem Knesebeck A; Department of Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, Germany.
Byrne J; Boyne Research Institute, Drogheda, Ireland.
van Dulmen-den Broeder E; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Hematology and Oncology, VU Medical Center, Amsterdam, the Netherlands.
Crocco M; Department of Neurooncology, Istituto Giannina Gaslini, Genova, Italy.
Grabow D; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Kaatsch P; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Kaiser M; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Spix C; German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Kenborg L; Danish Cancer Society Research Center, Childhood Cancer Research Group, Copenhagen, Denmark.
Winther JF; Danish Cancer Society Research Center, Childhood Cancer Research Group, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
Rechnitzer C; Copenhagen University Hospital Rigshospitalet, Department of Pediatrics and Adolescent Medicine, Copenhagen, Denmark.
Hasle H; Aarhus University Hospital, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark.
Kepak T; University Hospital Brno, Brno, Czech Republic; International Clinical Research Center (FNUSA-ICRC), Brno, Czech Republic.
van der Kooi AF; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Obstetrics and Gynecology, Erasmus MC - Sophia Children's Hospital, the Netherlands.
Kremer LC; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Oncology, Academic Medical Center Amsterdam, Amsterdam, the Netherlands.
Kruseova J; Department of Children Hemato-Oncology, Motol University Hospital Prague, Prague, Czech Republic.
Bielack S; Department of Pediatric Oncology, Hematology, Immunology, Stuttgart Cancer Center, Olgahospital, Stuttgart, Germany.
Sorg B; Department of Pediatric Oncology, Hematology, Immunology, Stuttgart Cancer Center, Olgahospital, Stuttgart, Germany.
Hecker-Nolting S; Department of Pediatric Oncology, Hematology, Immunology, Stuttgart Cancer Center, Olgahospital, Stuttgart, Germany.
Kuehni CE; Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Paediatric Oncology, Dept. of Paediatrics, Inselspital, University of Bern, Switzerland.
Ansari M; Department of Pediatrics, Oncology and Hematology Unit, University Hospital of Geneva, Cansearch Research Laboratory, Geneva University, Switzerland.
Kompis M; Department of Otolaryngology, Head and Neck Surgery, Inselspital, University of Berne, Switzerland.
van der Pal H; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Oncology, Academic Medical Center Amsterdam, Amsterdam, the Netherlands.
Parfitt R; Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
Deuster D; Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
Matulat P; Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
Tillmanns A; Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
Tissing WJE; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Beck JD; Hospital for Children and Adolescents, University of Erlangen-Nuremberg, Erlangen, Germany.
Elsner S; Institute for Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany.
Am Zehnhoff-Dinnesen A; Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University, Münster, Germany.
van den Heuvel-Eibrink MM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Department of Pediatric Oncology, Erasmus MC - Sophia Children's Hospital, Rotterdam, the Netherlands.
Zolk O; Institute of Clinical Pharmacology, Immanuel Klinik Rüdersdorf, Brandenburg Medical School Theodor Fontane, Germany; Institute of Pharmacology of Natural Products and Clinical Pharmacology, Ulm University Medical Center, Ulm, Germany. Electronic address: .; Pokaż więcej
Corporate Authors :: PanCareLIFE consortium
Źródło :: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 Oct; Vol. 138, pp. 212-224. Date of Electronic Publication: 2020 Sep 06.
Typ publikacji :: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :: Cancer Survivors*
Pharmacogenomic Variants*
Polymorphism, Single Nucleotide*
Antineoplastic Agents/*adverse effects
Carboplatin/*adverse effects
Cisplatin/*adverse effects
Hearing/*drug effects
Hearing Loss, Sensorineural/*genetics
Neoplasms/*drug therapy
Organic Cation Transporter 2/*genetics
Adolescent ; Age of Onset ; Child ; Child, Preschool ; Cross-Sectional Studies ; Europe ; Female ; Genetic Association Studies ; Genetic Predisposition to Disease ; Hearing Loss, Sensorineural/chemically induced ; Hearing Loss, Sensorineural/physiopathology ; Humans ; Infant ; Infant, Newborn ; Male ; Ototoxicity ; Pharmacogenomic Testing ; Prospective Studies ; Retrospective Studies ; Risk Assessment ; Risk Factors
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.
Autorzy :: Zazuli Z; Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.; Department of Pharmacology-Clinical Pharmacy, School of Pharmacy, Bandung Institute of Technology, Jawa Barat 40132, Indonesia.
Duin NJCB; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.
Jansen K; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.
Vijverberg SJH; Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Maitland-van der Zee AH; Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Masereeuw R; Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.; Pokaż więcej
Źródło :: International journal of molecular sciences [Int J Mol Sci] 2020 Sep 10; Vol. 21 (18). Date of Electronic Publication: 2020 Sep 10.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Pharmacogenomic Variants*
Kidney/*metabolism
Organic Cation Transport Proteins/*genetics
Renal Insufficiency/*chemically induced
Animals ; Humans ; Organic Cation Transport Proteins/metabolism ; Renal Insufficiency/metabolism
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 8 8.

Tytuł :: Pharmacogenomics of Antibiotics.
Autorzy :: Stocco G; Department of Life Sciences, University of Trieste, I-34128 Trieste, Italy.
Lucafò M; Institute for Maternal and Child Health-IRCCS 'Burlo Garofolo', I-34137 Trieste, Italy.
Decorti G; Institute for Maternal and Child Health-IRCCS 'Burlo Garofolo', I-34137 Trieste, Italy.; Department of Medicine, Surgery and Health Sciences, University of Trieste, I-34149 Trieste, Italy.; Pokaż więcej
Źródło :: International journal of molecular sciences [Int J Mol Sci] 2020 Aug 19; Vol. 21 (17). Date of Electronic Publication: 2020 Aug 19.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Pharmacogenomic Variants*
Anti-Bacterial Agents/*therapeutic use
Bacterial Infections/*genetics
Anti-Bacterial Agents/adverse effects ; Anti-Bacterial Agents/pharmacokinetics ; Bacterial Infections/drug therapy ; Genome-Wide Association Study/methods ; HLA Antigens/genetics ; Humans ; Precision Medicine/methods
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 9 9.

Tytuł :: Association between CYP2C9 polymorphisms and ischemic stroke following endovascular neurointervention.
Autorzy :: Sreedharan S; Melbourne Brain Centre, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Department of Medicine, University of Melbourne, Parkville, VIC 3050, Australia.
Churilov L; Florey Institute of Neuroscience and Mental Health, Heidelberg, VIC 3084, Australia.
Chan J; Department of Medicine, University of Melbourne, Parkville, VIC 3050, Australia; Department of Neuroscience, CCS, Monash University, Melbourne, VIC 3004, Australia.
Todaro M; Department of Medicine, University of Melbourne, Parkville, VIC 3050, Australia; Department of Neurology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Department of Neuroscience, CCS, Monash University, Melbourne, VIC 3004, Australia.
Coulthard A; Department of Medical Imaging, Royal Brisbane and Women's Hospital, QLD 4029, Australia; Academic Discipline of Medical Imaging, University of Queensland, QLD 4072, Australia.
Hocking J; Department of Medical Imaging, Royal Brisbane and Women's Hospital, QLD 4029, Australia; Academic Discipline of Medical Imaging, University of Queensland, QLD 4072, Australia.
Mahady K; Department of Medical Imaging, Royal Brisbane and Women's Hospital, QLD 4029, Australia; Academic Discipline of Medical Imaging, University of Queensland, QLD 4072, Australia.
Mitchell P; Department of Radiology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Department of Radiology, University of Melbourne, Parkville, VIC 3050, Australia.
Dowling R; Department of Radiology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Department of Radiology, University of Melbourne, Parkville, VIC 3050, Australia.
Bush S; Department of Radiology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Department of Radiology, University of Melbourne, Parkville, VIC 3050, Australia.
Kwan P; Melbourne Brain Centre, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Department of Medicine, University of Melbourne, Parkville, VIC 3050, Australia; Department of Neurology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Department of Neuroscience, CCS, Monash University, Melbourne, VIC 3004, Australia; Department of Neurology, Alfred Health, Melbourne, VIC 3004, Australia.
Yan B; Melbourne Brain Centre, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Department of Medicine, University of Melbourne, Parkville, VIC 3050, Australia; Department of Neurology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia; Department of Radiology, Royal Melbourne Hospital, Parkville, VIC 3050, Australia. Electronic address: .; Pokaż więcej
Źródło :: Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association [J Stroke Cerebrovasc Dis] 2020 Aug; Vol. 29 (8), pp. 104901. Date of Electronic Publication: 2020 May 19.
Typ publikacji :: Journal Article; Multicenter Study
MeSH Terms :: Pharmacogenomic Variants*
Polymorphism, Single Nucleotide*
Brain Ischemia/*genetics
Brain Ischemia/*prevention & control
Cerebrovascular Disorders/*therapy
Cytochrome P-450 CYP2C9/*genetics
Endovascular Procedures/*adverse effects
Stroke/*genetics
Stroke/*prevention & control
Aged ; Brain Ischemia/diagnosis ; Clopidogrel/pharmacokinetics ; Cytochrome P-450 CYP2C9/metabolism ; Female ; Humans ; Male ; Middle Aged ; Pilot Projects ; Platelet Aggregation Inhibitors/pharmacokinetics ; Prospective Studies ; Protective Factors ; Queensland ; Risk Assessment ; Risk Factors ; Stroke/diagnosis ; Time Factors ; Treatment Outcome ; Victoria
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Human essential hypertension: no significant association of polygenic risk scores with antihypertensive drug responses.
Autorzy :: Sánez Tähtisalo H; Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Ruotsalainen S; Institute for Molecular Medicine Finland, Helsinki Institute of Life Sciences, University of Helsinki, Helsinki, Finland.
Mars N; Institute for Molecular Medicine Finland, Helsinki Institute of Life Sciences, University of Helsinki, Helsinki, Finland.
Porthan K; Division of Cardiology, Heart and Lung Center, University of Helsinki and Helsinki, University Central Hospital, Helsinki, Finland.; Department of Medicine, University of Helsinki and Minerva Foundation Institute for Medical Research, Helsinki, Finland.
Oikarinen L; Division of Cardiology, Heart and Lung Center, University of Helsinki and Helsinki, University Central Hospital, Helsinki, Finland.
Virolainen J; Division of Cardiology, Heart and Lung Center, University of Helsinki and Helsinki, University Central Hospital, Helsinki, Finland.
Fyhrquist F; Minerva Foundation Institute for Medical Research, Helsinki, Finland.
Ripatti S; Institute for Molecular Medicine Finland, Helsinki Institute of Life Sciences, University of Helsinki, Helsinki, Finland.; Department of Public Health, University of Helsinki, Helsinki, Finland.
Kontula KK; Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Hiltunen TP; Department of Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. .; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland. .; Pokaż więcej
Źródło :: Scientific reports [Sci Rep] 2020 Jul 20; Vol. 10 (1), pp. 11940. Date of Electronic Publication: 2020 Jul 20.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Genetic Predisposition to Disease*
Multifactorial Inheritance*
Pharmacogenomic Variants*
Essential Hypertension/*etiology
Aged ; Antihypertensive Agents/pharmacology ; Antihypertensive Agents/therapeutic use ; Biomarkers ; Blood Pressure/drug effects ; Drug Resistance ; Essential Hypertension/drug therapy ; Essential Hypertension/pathology ; Essential Hypertension/physiopathology ; Female ; Humans ; Hypertrophy, Left Ventricular/drug therapy ; Hypertrophy, Left Ventricular/etiology ; Male ; Middle Aged ; Treatment Outcome
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 11 11.

Tytuł :: LRP1 and APOA1 Polymorphisms: Impact on Warfarin International Normalized Ratio-Related Phenotypes.
Autorzy :: Li D; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.; Institute of Clinical Pharmacology, Central South University Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.; Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.; National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, P. R. China.
Luo ZY; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha P. R. China.
Chen Y; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.; Institute of Clinical Pharmacology, Central South University Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.; Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.; National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, P. R. China.
Zhu H; Department of Cardiovascular Surgery, Xiangya Hospital, Central South University, Changsha P. R. China.
Song GB; Department of Cardio-Thoracic Surgery, the Second Xiangya Hospital, Central South University, Changsha P. R. China.
Zhou XM; Department of Cardio-Thoracic Surgery, the Second Xiangya Hospital, Central South University, Changsha P. R. China.
Yan H; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha P. R. China.
Zhou HH; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.; Institute of Clinical Pharmacology, Central South University Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.; Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.; National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, P. R. China.; Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
Zhang W; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.; Institute of Clinical Pharmacology, Central South University Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.; Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.; National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, P. R. China.; Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
Li X; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.; Institute of Clinical Pharmacology, Central South University Hunan Key Laboratory of Pharmacogenetics, Changsha, P. R. China.; Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, P.R. China.; National Clinical Research Center for Geriatric Disorders, Changsha, Hunan, P. R. China.; Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.; Pokaż więcej
Źródło :: Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 2020 Jul; Vol. 76 (1), pp. 71-76.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Drug Monitoring*
International Normalized Ratio*
Pharmacogenomic Variants*
Polymorphism, Single Nucleotide*
Anticoagulants/*therapeutic use
Apolipoprotein A-I/*genetics
Blood Coagulation/*drug effects
Blood Coagulation/*genetics
Low Density Lipoprotein Receptor-Related Protein-1/*genetics
Warfarin/*therapeutic use
Adult ; Female ; Humans ; Male ; Middle Aged ; Phenotype
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Genetic variations in drug-metabolizing enzyme CYP2C9 among major ethnic groups of Pakistani population.
Autorzy :: Hizbullah; Department of Biochemistry, Abdul Wali Khan University Mardan (AWKUM), Mardan-23200, Khyber Pakhtunkhwa, Pakistan.
Ahmed S; Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, H-8/4, Islamabad.
Noor Mumtaz M; Department of Biochemistry, Abdul Wali Khan University Mardan (AWKUM), Mardan-23200, Khyber Pakhtunkhwa, Pakistan.
Zulfiqar Z; Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, H-8/4, Islamabad.
Amir Hamza S; Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, H-8/4, Islamabad.
Siraj S; Institute of Basic Medical Sciences, Khyber Medical University, Peshawar, Pakistan.
Jelani M; Center for Omics Sciences, Islamia College Peshawar, Pakistan.
Imran I; Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan.
Khan A; Department of Biochemistry, Abdul Wali Khan University Mardan (AWKUM), Mardan-23200, Khyber Pakhtunkhwa, Pakistan. Electronic address: .; Pokaż więcej
Źródło :: Gene [Gene] 2020 Jul 01; Vol. 746, pp. 144659. Date of Electronic Publication: 2020 Apr 07.
Typ publikacji :: Clinical Trial; Journal Article
MeSH Terms :: Alternative Splicing*
Pharmacogenomic Variants*
Polymorphism, Single Nucleotide*
Cytochrome P-450 CYP2C9/*genetics
Ethnic Groups/*genetics
Cytochrome P-450 CYP2C9/metabolism ; Female ; Humans ; Male ; Pakistan/ethnology ; Warfarin/pharmacokinetics ; Warfarin/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.
Autorzy :: Lewis JP; Department of Medicine and Program for Personalized and Genomic Medicine, University of Maryland, 670 W. Baltimore St., Baltimore, MD 21201, USA.
Backman JD; Department of Medicine and Program for Personalized and Genomic Medicine, University of Maryland, 670 W. Baltimore St., Baltimore, MD 21201, USA.
Reny JL; Department of Internal Medicine, Béziers Hospital, 2 Rue Valentin Hau, BP 740, Béziers 34525, France.; Department of Medicine, Geneva Platelet Group, University of Geneva School of Medicine, University Hospitals of Geneva, 24 rue du Général-Dufour, Genève 4 CH-1211, Switzerland.
Bergmeijer TO; Department of Cardiology, Antonius Center for Platelet Function Research, St Antonius Hospital, P O Box 2500, Nieuwegein 3432 EM, The Netherlands.
Mitchell BD; Department of Medicine and Program for Personalized and Genomic Medicine, University of Maryland, 670 W. Baltimore St., Baltimore, MD 21201, USA.; Geriatrics Research and Education Clinical Center, Baltimore Veterans Administration Medical Center, 10 N. Greene St., Baltimore, MD 21201, USA.
Ritchie MD; Center for Translational Bioinformatics, Institute for Biomedical Informatics, University of Pennsylvania, A301 Richards Building, 3700 Hamilton Walk, Philadelphia, PA 19104, USA.
Déry JP; Quebec Heart and Lung Institute, University Laval, 2725 chemin Sainte-Foy, Quebec City G1V 4G5, Canada.
Pakyz RE; Department of Medicine and Program for Personalized and Genomic Medicine, University of Maryland, 670 W. Baltimore St., Baltimore, MD 21201, USA.
Gong L; Department of Biomedical Data Science, Stanford University, 443 Via Ortega, Room 213, Stanford, CA 94305, USA.
Ryan K; Department of Medicine and Program for Personalized and Genomic Medicine, University of Maryland, 670 W. Baltimore St., Baltimore, MD 21201, USA.
Kim EY; Department of Clinical Pharmacology, Inje University, Busan Paik Hospital, Bokji-ro 75, Busangjin-gu, Busan 614-735, South Korea.
Aradi D; Department of Cardiology, Heart Center Balatonfüred, 2 Gyogy Ter, Balatonfured 8230, Hungary.
Fernandez-Cadenas I; Stroke Pharmacogenomics and Genetic Group, Fundació Docencia i Recerca Mutuaterrassa, 508221 Terrassa, Barcelona 8041, Spain.; Department of Neurology, Vall d'Hebron Institute of Research, Passeig Vall d'Hebron, Barcelona 8035, Spain.
Lee MTM; Genomic Medicine Institute, Geisinger Health System, 100 N. Academy Ave., Danville, PA 17822, USA.
Whaley RM; Department of Biomedical Data Science, Stanford University, 443 Via Ortega, Room 213, Stanford, CA 94305, USA.
Montaner J; Neurovascular Research Laboratory, Vall d'Hebron Institute of Research, Passeig Vall d'Hebron 119-129, Barcelona 8035, Spain.
Gensini GF; Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla, Florence 50055, Italy.
Cleator JH; Division of Cardiology, Vanderbilt University Medical Center, 2215B Garland Avenue, Nashville, TN 37232, USA.; Department of Pharmacology, Vanderbilt University Medical Center, 2215B Garland Avenue, Nashville, TN 37232, USA.
Chang K; Department of Internal Medicine, Cardiology Division, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-Gu, Seoul 6591, South Korea.
Holmvang L; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Inge Lehmannsvej 7 - 2142, Copenhagen 2100, Denmark.
Hochholzer W; Department of Cardiology and Angiology II, University Heart Center Freiburg, Suedring 15, Bad Krozingen 79189, Germany.
Roden DM; Department of Pharmacology, Vanderbilt University Medical Center, 2215B Garland Avenue, Nashville, TN 37232, USA.; Department of Medicine, Vanderbilt University Medical Center, 2215B Garland Avenue, Nashville, TN 37232, USA.; Department of Biomedical Informatics, Vanderbilt University Medical Center, 2215B Garland Avenue, Nashville, TN 37232, USA.
Winter S; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, Stuttgart, 70376 Germany.
Altman RB; Department of Bioengineering, Genetics, and Medicine, Stanford University, 443 Via Ortega Drive, Shriram Room 209, Stanford, CA 94305, USA.
Alexopoulos D; Department of Cardiology, Patras University Hospital, Rio, Patras 26500, Greece.
Kim HS; Department of Clinical Pharmacology, Inje University, Busan Paik Hospital, Gaegum2-dong 622-165, Busanjin-Gu, Busan 614-735, South Korea.
Gawaz M; Department of Cardiology and Angiology, University of Tübingen, Otfired-Müller-Straße 10, Tübingen 72076, Germany.
Bliden KP; Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, 3300 Gallows Rd, Falls Church, VA 22042, USA.
Valgimigli M; Department of Cardiology, Bern University Hospital, Freiburgstrasse 8, Bern 3010, Switzerland.
Marcucci R; Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla, Florence 50055, Italy.; Atherothrombotic Diseases Center, Careggi University Hospital, Largo G. Alessandro Brambilla, Florence 50134, Italy.
Campo G; Department of Cardiology, University Hospital of Ferrara, Via Aldo Moro 8, Cona (FE), Ferrara 44123, Italy.; GVM Care & Research, Maria Cecilia Hospital, Via Madonna di Genova, 1, Cotignola 48033, Italy.
Schaeffeler E; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, Stuttgart, 70376 Germany.
Dridi NP; Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Inge Lehmannsvej 7 - 2142, Copenhagen 2100, Denmark.
Wen MS; Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou and School of Medicine, Chang Gung University, No. 5, Fuxing St, Guishan Dist., Taoyuan City 333, Taiwan.
Shin JG; Department of Clinical Pharmacology, Inje University, Busan Paik Hospital, Gaegum2-dong 622-165, Busanjin-Gu, Busan 614-735, South Korea.
Fontana P; Department of Medicine, Geneva Platelet Group, University of Geneva School of Medicine, University Hospitals of Geneva, 24 rue du Général-Dufour, Genève 4 CH-1211, Switzerland.; Division of Angiology and Haemostasis, University Hospitals of Geneva, 24 Rue Gabrielle-Perret-Gentil, Geneva 1205, Switzerland.
Giusti B; Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla, Florence 50055, Italy.; Atherothrombotic Diseases Center, Careggi University Hospital, Largo G. Alessandro Brambilla, Florence 50134, Italy.
Geisler T; Department of Cardiology and Angiology, University of Tübingen, Otfired-Müller-Straße 10, Tübingen 72076, Germany.
Kubo M; Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, 1-7-22, Suehiro-cho, Tsurumi, Yokohama 230-0045, Japan.
Trenk D; Department of Cardiology and Angiology II, Clinical Pharmacology, University Heart Centre Freiburg, Suedring 15, Bad Krozingen D-79189, Germany.
Siller-Matula JM; Department of Cardiology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria.
Ten Berg JM; Department of Cardiology, Antonius Center for Platelet Function Research, St Antonius Hospital, P O Box 2500, Nieuwegein 3432 EM, The Netherlands.
Gurbel PA; Department of Cardiology and Angiology, University of Tübingen, Otfired-Müller-Straße 10, Tübingen 72076, Germany.
Schwab M; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, Stuttgart, 70376 Germany.; Department of Clinical Pharmacology, University of Tuebingen, Otfried-Mueller-Strasse 10, Tuebingen 72076, Germany.; Department of Pharmacy and Biochemistry, University of Tuebingen, Otfried-Mueller-Strasse 10, Tuebingen 72076, Germany.
Klein TE; Department of Biomedical Data Science, Stanford University, 443 Via Ortega, Room 213, Stanford, CA 94305, USA.; Department of Bioengineering, Genetics, and Medicine, Stanford University, 443 Via Ortega Drive, Shriram Room 209, Stanford, CA 94305, USA.
Shuldiner AR; Department of Medicine and Program for Personalized and Genomic Medicine, University of Maryland, 670 W. Baltimore St., Baltimore, MD 21201, USA.; Pokaż więcej
Corporate Authors :: ICPC Investigators
Źródło :: European heart journal. Cardiovascular pharmacotherapy [Eur Heart J Cardiovasc Pharmacother] 2020 Jul 01; Vol. 6 (4), pp. 203-210.
Typ publikacji :: Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :: Decision Support Techniques*
Percutaneous Coronary Intervention*/adverse effects
Percutaneous Coronary Intervention*/instrumentation
Percutaneous Coronary Intervention*/mortality
Pharmacogenomic Variants*
Polymorphism, Single Nucleotide*
Clopidogrel/*therapeutic use
Coronary Artery Disease/*therapy
Platelet Aggregation/*drug effects
Platelet Aggregation Inhibitors/*therapeutic use
Aged ; Brain Ischemia/mortality ; Brain Ischemia/prevention & control ; Clopidogrel/adverse effects ; Coronary Artery Disease/blood ; Coronary Artery Disease/diagnosis ; Coronary Artery Disease/mortality ; Coronary Thrombosis/mortality ; Coronary Thrombosis/prevention & control ; Europe ; Female ; Humans ; Male ; Middle Aged ; Myocardial Infarction/mortality ; Myocardial Infarction/prevention & control ; Platelet Aggregation/genetics ; Platelet Aggregation Inhibitors/adverse effects ; Predictive Value of Tests ; Risk Assessment ; Risk Factors ; Stents ; Stroke/mortality ; Stroke/prevention & control ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Association Between Number of Actionable Pharmacogenetic Variants and Length of Hospital Stay.
Autorzy :: Finkelstein J; Icahn School of Medicine at Mount Sinai, USA.
Zhang F; Columbia University Irving Medical Center, USA.
Cabrera M; Columbia University Irving Medical Center, USA.; Pokaż więcej
Źródło :: Studies in health technology and informatics [Stud Health Technol Inform] 2020 Jun 26; Vol. 272, pp. 195-198.
Typ publikacji :: Journal Article
MeSH Terms :: Pharmacogenomic Variants*
Adult ; Aged ; Aged, 80 and over ; Electronic Health Records ; Humans ; Length of Stay ; Linear Models ; Middle Aged ; Pharmacogenetics ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Characterization of pharmacogenetic markers related to Acute Lymphoblastic Leukemia toxicity in Amazonian native Americans population.
Autorzy :: de Carvalho DC; Oncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Wanderley AV; Oncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.; Departamento de Pediatria, Ophir Loyola Hospital, Belém, PA, Brazil.
Dos Santos AMR; Human and Medical Genetics Laboratory, Instituto de Ciências Biológicas, Universidade Federal Do Pará, Belém, PA, Brazil.
Moreira FC; Oncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
de Sá RBA; Oncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Fernandes MR; Oncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Modesto AAC; Oncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
de Souza TP; Oncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Cohen-Paes A; Oncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Leitão LPC; Oncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
Rodrigues JCG; Oncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
da Silva ALDC; Genomics and Bioinformatics Laboratory, Instituto de Ciências Biológicas, Universidade Federal Do Pará, Belém, Brazil.
Guerreiro JF; Human and Medical Genetics Laboratory, Instituto de Ciências Biológicas, Universidade Federal Do Pará, Belém, PA, Brazil.
Santos S; Oncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.; Human and Medical Genetics Laboratory, Instituto de Ciências Biológicas, Universidade Federal Do Pará, Belém, PA, Brazil.
Khayat AS; Oncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.
de Assumpção PP; Oncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil.; João de Barros Barreto University Hospital, Universidade Federal Do Pará, Belém, PA, Brazil.
Dos Santos NPC; Oncology Research Nucleus, Universidade Federal Do Pará, Belém, PA, Brazil. .; Human and Medical Genetics Laboratory, Instituto de Ciências Biológicas, Universidade Federal Do Pará, Belém, PA, Brazil. .; Hospital Universitário João de Barros Barreto - Núcleo de Pesquisa Em Oncologia, 2º Piso da Unidade de Alta Complexidade Em Oncologia. Av. Mundurucus, 4487, Guamá, Belém, PA, 66073-005, Brazil. .; Pokaż więcej
Źródło :: Scientific reports [Sci Rep] 2020 Jun 24; Vol. 10 (1), pp. 10292. Date of Electronic Publication: 2020 Jun 24.
Typ publikacji :: Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :: Pharmacogenomic Variants*
Antineoplastic Agents/*pharmacology
Indians, South American/*genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
Antineoplastic Agents/therapeutic use ; Brazil ; Child ; Child, Preschool ; Female ; Genetic Markers ; Humans ; Male ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 16 16.

Tytuł :: The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy.
Autorzy :: Saberi M; Department of Medical Chemistry, School of Pharmacy, Ahvaz Jundishpur University of Medical Sciences, Ahvaz, Iran.
Ramazani Z; Department of Medical Chemistry, School of Pharmacy, Ahvaz Jundishpur University of Medical Sciences, Ahvaz, Iran.
Rashidi H; Diabetic Research Center, Ahvaz Jundishpur University of Medical Sciences, Ahvaz, Iran.
Saberi A; Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.; Pokaż więcej
Źródło :: Vascular health and risk management [Vasc Health Risk Manag] 2020 Jun 18; Vol. 16, pp. 241-248. Date of Electronic Publication: 2020 Jun 18 (Print Publication: 2020).
Typ publikacji :: Journal Article
MeSH Terms :: Pharmacogenomic Variants*
Blood Glucose/*drug effects
Cytochrome P-450 CYP2C9/*genetics
Diabetes Mellitus, Type 2/*drug therapy
Diabetic Nephropathies/*genetics
Diabetic Retinopathy/*genetics
Gliclazide/*therapeutic use
Glyburide/*therapeutic use
Hypoglycemic Agents/*therapeutic use
Biomarkers/blood ; Blood Glucose/metabolism ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/genetics ; Diabetic Nephropathies/diagnosis ; Diabetic Retinopathy/diagnosis ; Female ; Gene Frequency ; Gliclazide/adverse effects ; Gliclazide/blood ; Glyburide/adverse effects ; Glyburide/blood ; Humans ; Hypoglycemia/chemically induced ; Hypoglycemia/genetics ; Hypoglycemic Agents/adverse effects ; Hypoglycemic Agents/blood ; Male ; Middle Aged ; Risk Factors ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy.
Autorzy :: Al-Rubaish AM; Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Al-Muhanna FA; Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Alshehri AM; Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Al-Mansori MA; Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Alali RA; Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Khalil RM; Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Al Faraidy KA; Department of Cardiology, King Fahd Armed Forces Hospital, Dhahran, Saudi Arabia.
Cyrus C; Department of Clinical Biochemistry, College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia.
Sulieman MM; Department of Internal Medicine, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Vatte C; Department of Cardiology, King Fahd Armed Forces Hospital, Dhahran, Saudi Arabia.
Claassens DMF; Department of Cardiology, Saint Antonius Hospital, Nieuwegein, The Netherlands.
Ten Berg JM; Department of Cardiology, Saint Antonius Hospital, Nieuwegein, The Netherlands.
Asselbergs FW; Department of Cardiology, University Medical Center Utrecht, ICIN-Netherlands Heart Institute, Durrer Centre for Cardiogenetic Research, Utrecht, The Netherlands.; Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, UK.
Al-Ali AK; Department of Clinical Biochemistry, College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia. .; Pokaż więcej
Źródło :: BMC cardiovascular disorders [BMC Cardiovasc Disord] 2020 Jun 03; Vol. 20 (1), pp. 268. Date of Electronic Publication: 2020 Jun 03.
Typ publikacji :: Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Percutaneous Coronary Intervention*/adverse effects
Percutaneous Coronary Intervention*/instrumentation
Pharmacogenomic Testing*
Pharmacogenomic Variants*
Point-of-Care Testing*
Polymorphism, Genetic*
Coronary Thrombosis/*prevention & control
Cytochrome P-450 CYP2C19/*genetics
Platelet Aggregation Inhibitors/*administration & dosage
ST Elevation Myocardial Infarction/*therapy
Clinical Decision-Making ; Clopidogrel/administration & dosage ; Coronary Thrombosis/etiology ; Humans ; Multicenter Studies as Topic ; Patient Selection ; Platelet Aggregation Inhibitors/adverse effects ; Prasugrel Hydrochloride/administration & dosage ; Predictive Value of Tests ; Prospective Studies ; Randomized Controlled Trials as Topic ; ST Elevation Myocardial Infarction/diagnosis ; ST Elevation Myocardial Infarction/genetics ; Saudi Arabia ; Stents ; Ticagrelor/administration & dosage ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial.
Autorzy :: León-Cachón RBR; Center of Molecular Diagnostics and Personalized Medicine, Department of Basic Sciences, Division of Health Sciences, University of Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico. .
Bamford AD; Center of Molecular Diagnostics and Personalized Medicine, Department of Basic Sciences, Division of Health Sciences, University of Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico.
Meester I; Center of Molecular Diagnostics and Personalized Medicine, Department of Basic Sciences, Division of Health Sciences, University of Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico.
Barrera-Saldaña HA; Vitagenesis S.A., Monterrey, Nuevo Leon, Mexico.; Innbiogem S.C., Monterrey, Nuevo Leon, Mexico.
Gómez-Silva M; Forensic Medicine Service, School of Medicine, Autonomous University of Nuevo Leon, Monterrey, Nuevo Leon, Mexico.; Analytical Department of the Research Institute for Clinical and Experimental Pharmacology, Ipharma S.A., Monterrey, Nuevo Leon, Mexico.
Bustos MFG; Institute of Experimental Pathology (CONICET), Faculty of Health Sciences, National University of Salta, Salta, Argentina.; University School in Health Sciences, Catholic University of Salta, Salta, Argentina.; Pokaż więcej
Źródło :: Scientific reports [Sci Rep] 2020 Jun 01; Vol. 10 (1), pp. 8900. Date of Electronic Publication: 2020 Jun 01.
Typ publikacji :: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :: Pharmacogenomic Variants*
Atorvastatin/*administration & dosage
Atorvastatin/*blood
Liver-Specific Organic Anion Transporter 1/*genetics
ATP Binding Cassette Transporter, Subfamily B/genetics ; Adult ; Arylamine N-Acetyltransferase/genetics ; Atorvastatin/pharmacokinetics ; Catechol O-Methyltransferase/genetics ; Chromatography, Liquid ; Cross-Over Studies ; Cytochrome P-450 CYP2D6/genetics ; Genotyping Techniques ; Healthy Volunteers ; Humans ; Male ; Mass Spectrometry ; Mexico ; Polymorphism, Single Nucleotide ; Single-Blind Method ; Young Adult
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 19 19.

Tytuł :: Pharmacogenomics for the efficacy of platinum-based chemotherapy: Old drugs, new integrated perspective.
Autorzy :: Mao CX; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, PR China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, PR China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha 410078, PR China.
Li M; Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, PR China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, PR China.
Zhang W; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, PR China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, PR China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha 410078, PR China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, PR China.
Zhou HH; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, PR China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, PR China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha 410078, PR China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, PR China.
Yin JY; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, PR China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, PR China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha 410078, PR China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, PR China. Electronic address: .
Liu ZQ; Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, PR China; Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, PR China; Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha 410078, PR China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, PR China. Electronic address: .; Pokaż więcej
Źródło :: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2020 Jun; Vol. 126, pp. 110057. Date of Electronic Publication: 2020 Mar 04.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Pharmacogenomic Variants*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biomarkers, Tumor/*genetics
Carboplatin/*therapeutic use
Cisplatin/*therapeutic use
Pharmacogenetics/*methods
Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Carboplatin/pharmacokinetics ; Cisplatin/pharmacokinetics ; DNA Repair/drug effects ; DNA Repair/genetics ; Genome-Wide Association Study ; Humans
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer.
Autorzy :: Papachristos A; Laboratory of Pharmacokinetics, Department of Pharmacy, School of Health Sciences, University of Patras, 26504 Patra, Greece.
Karatza E; Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15771 Athens, Greece.; Institute of Applied and Computational Mathematics (IACM)/Foundation of Research and Technology Hellas (FORTH), 70013 Heraklion, Greece.
Kalofonos H; Division of Medical Oncology, University Hospital of Patras, 26504 Patra, Greece.
Sivolapenko G; Laboratory of Pharmacokinetics, Department of Pharmacy, School of Health Sciences, University of Patras, 26504 Patra, Greece.; Pokaż więcej
Źródło :: International journal of molecular sciences [Int J Mol Sci] 2020 May 26; Vol. 21 (11). Date of Electronic Publication: 2020 May 26.
Typ publikacji :: Journal Article
MeSH Terms :: Pharmacogenomic Variants*
Angiogenesis Inhibitors/*pharmacokinetics
Bevacizumab/*pharmacokinetics
Colorectal Neoplasms/*drug therapy
Aged ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/therapeutic use ; Bevacizumab/administration & dosage ; Bevacizumab/therapeutic use ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Female ; Humans ; Intercellular Adhesion Molecule-1/genetics ; Male ; Metabolic Clearance Rate ; Middle Aged ; Neoplasm Metastasis ; Polymorphism, Single Nucleotide ; Vascular Endothelial Growth Factor A/genetics
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Pharmacogenomic Variants"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język